The CD56+ cells freshly isolated from human peripheral blood contain a substantial subset of CD14+CD86+HLA-DR+ cells which spontaneously differentiate into enlarged DC (dendritic cell)-like cells. We show here that interferon-α (IFN-α)-induced DC-like cells expressing high levels of CD56 and CD14 (hereafter, CD56
Introduction
γδT cells are unconventional T cells playing a major role in innate immune responses against microbes, stressed cells, and tumor cells [1] . In humans, most of our knowledge about the specificity and biological role of γδT cells is derived from analysis of a major peripheral subset referred to as Vγ9Vδ2T cells, comprising 5-10% of all circulating T cells [2] . Unlike classical αβ T cells, the Vγ9Vδ2T cells can interact with low molecular mass phosphate-containing, nonprocessed antigens, such as pyrophosphomonoesters and alkyl amine in an HLA independent manner [3, 4] . Aminobisphosphonates, such as pamidronate and zoledronate, which were originally developed as therapeutic drugs for osteoporosis but are increasingly used for cancer therapy, have also been shown to activate Vγ9γδT cells in an HLA independent manner, and the aminobisphosphonateactivated Vγ9γβT cells were functionally characterized in vitro and in vivo [5] [6] [7] . In contrast to pyrophosphomonoesters, the Vγ9γδT cell-activation by aminobisphosphonates is highly dependent on the presence of antigen presenting cells (APCs) including monocytes and DCs [8, 9] . Aminobisphosphonates appear to target the mevalonate pathway of the APCs and induce the accumulation of phosphorylated metabolities, such as isopentenyl pyrophosphates, which are recognized by the Vγ9γδT cell.
It is well established that human Vγ9γδT cells can recognize ligands expressed by tumor cells and that they exert strong cytotoxic activity against tumor cell lines [10] [11] [12] . The activated Vγ9γδT cells rapidly release Th1 cytokine such as IFNα and TNFα, enhancing antitumor activity by inhibiting tumor growth and activating components of the adaptive immune system [13, 14] . Recently, adoptive transfer of ex vivo-expanded autologous Vγ9γδT cells is being considered for development as a new immunotherapeutic approach for patients with cancer. The clinical trials with immunotherapy using Vγ9γδT cells for patients (Pts) with cancers, including multiple myeloma [15] , non-small cell lung cancer (NSCLC) [16] , renal cell carcinoma [17] and a variety of metastatic solid tumors [18] have been performed. In many cases with clinical trials, a large number of Vγ9γδT cells were expanded from PBMCs using zoledronate with high concentration of IL-2, however, the clinical responses were seen in a minority of patients, presumably, at least in part, as a result of insufficient expansion of Vγ9γδT cells possessing high effector function capable of eradicating tumor cells. Therefore, one of goals of an effective immunotherapy using Vγ9γδT cells against cancers is the induction of Vγ9γδT cells which have high effecter functions against tumor cells.
Among Vγ9γδT cells, CD56+Vγ9γδT cells have higher production of IFNγ and TNFα and higher cytotoxicity against tumor cells, in comparison with CD56-Vγ9γδT [13] . We 
Materials and Methods
The surface phenotypes were determined by single to fivecolor flow cytometry using an Epics XL MCL (Beckman Coulter, BC, CA). The following monoclonal antibodies (mAbs) were purchased from BC: anti-CD3(UCHT1), anti-Vγ9TCR(IMMU 360), anti-CD14(RM052), anti-CD16(3G8), anti-CD45(J.33), anti-CD54(84H10), anti-CD56(N901), anti-CD69(TPI.55.3), anti-HLADR(Immu-357), anti-CD80(MAB104), anti-CD86(HA5.2B7), anti-CD40(MAB89), anti-CD11c(BU15), anti-CD83(HB15a), anti-CD36(FA6.152), mouse IgG1(679.1Mc7), mouse IgG2a (7T4-IF5) and mouse IgG2b(A-1) mAbs. Anti-HLA-AB(G46-2.6) and anti-CCR7 (150503) mAbs were purchased from Beckton Dickinson (San Jose, CA) and R & D System (Minneapolis, MN), respectively. All mAbs were conjugated with FITC, PE, ECD, PC5, or PC7. Zoledronate was purchased from Novartis Pharmaceuticals (Basel, Switzerland).
Generation of CD56 high+

IFN-DCs
PBMCs were isolated from HDs and Pts with cancer including NSCLC, metastatic melanoma, cervical cancer, metastatic breast cancer, metastatic pancreatic cancer, metastatic sarcoma, and multiple myeloma. The in vitro study was approved by the Ethics Committee of the Biotherapy Institute of Japan and the Research Ethics Committee of the Queensland Institute of Medical Research, the University of Queensland. The in vivo study was approved by the Ethics Committee of the Biotherapy Institute of Japan. All the subjects provided written informed consent to use their PB. For cell culture in this study, AIM-V medium (Invitrogen, Tokyo, Japan) containing 10% heat-inactivated human AB serum was used. PBMCs separated by density gradient centrifugation with Lymphoprep (Nycomed, Oslo, Norway) were suspended in the medium and then incubated in a flask (Corning Incorporated, Japan) for 2 h at 37°C. After removing nonadherent cells, adherent cells were cultured in a fresh medium containing GM-CSF (1000U/mL; Primmune Inc., Japan) and IFN-α (1000U/ mL; INTRON, MSD K.K., Japan) for 3 days to obtain CD56 high+ IFNDCs. Alternatively, adherent cells were cultured for 5 days in the medium containing GM-CSF (1000U/mL; Primmune Inc., Japan) and IL-4 (500U/mL; Primmune Inc., Japan) to obtain IL-4DCs. The cells were further cultured for 2 days in the presence of TNFα (10ng/ mL: Peprotech Ltd., UK) to obtain mIL-4DCs. In the previous our study [19] , we compared monocytes obtained as adherent cells with purified CD14+ cells as starting materials. The results showed that the expression levels of CD56 on adherent cell-derived IFN-DCs were higher than that on purified CD14+ monocyte-derived IFN-DCs and then, we speculated that CD56 high+ IFN-DCs preferentially expand CD56+Vγ9γδT cells through adhesion molecules, CD56 [20] . Thus, we used adherent cells as starting materials in this study as well. 
Induction of
Determination of intracellular cytokine content
Following culture of lymphocytes with autologous CD56 high+ IFNDCs from cancer patients in the presence of zoledronate and IL-2 for 10 days, the expanded lymphocytes among which the mean percentages of Vγ9γδT cells from cancers patients including two NSCLC patients and two metastatic melanoma patients were 86.1 ± 9.1%, were separated into Vγ9γδT cells expressing high levels of CD56 (fraction A) (the mean percentage of CD56+ Vγ9γδT cells among Vγ9δT cells was 98.8% ± 0.2% from three Pts) and Vγ9γδT cells expressing low levels of CD56 (fraction B) (the mean percentage of CD56+ cells among Vγ9γδT cells was 8.0 ± 2.5%) using CD56 mAb-conjugated microbeads (Miltenyi Biotech). Each fraction, A or B was treated as described previously [13] . Then, each fraction was stained for surface markers of Vγ9γδT cells using anti-CD3-ECD, anti-CD56-PC5, and anti-Vγ9TCR-FITC mAbs. For the intracytoplasmic staining of cytokines, the each fraction was also treated as described previously [13] . Finally, each fraction was stained anti-IFNγ-PE or anti-TNFα-PE mAb (BC) for 20 min at 4 o C, washed with PBS containing 1% bovine serum albumin, and analyzed for the productions of IFNγ and TNFα using flow cytometry.
Blocking test with anti-CD56 mAb
To evaluate the involvement of CD56 in the preferential expansion of CD56+ Vγ9γδT cells by CD56 
Statistical analysis
P values were calculated using the paired/two-tailed Student's
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t-test and differences were considered significant at a p value <0.05 and highly significant at a p value <0.01. Representative data from HD1 and five cancer Pts following culture of lymphocytes with CD56 high+ IFN-DCs or mIL-4DCs for 8-14 days, were shown in Figure 3a . Before culture, the percentage of Vγ9γδT cells among lymphocytes was 8.6% for HD1, 9.6% for Pt.1, 9.3% for Pt2, 3.5% for Pt3, 4.6% for Pt4, and 3.9% for Pt7. To confirm the involvement of CD56 in preferential expansion of CD56+ Vγ9γδT cells by CD56 high+ IFN-DCs, the blocking experiment using anti-CD56mAbs was performed. As representative results from Pt4 with melanoma, the percentage of CD56+ Vγ9γδT cells decreased from 70.5% to 26.6% in the presence of anti-CD56 mAb (62.3% inhibition) and to 65.0% in the presence of IgG1 (7.8% inhibition) (Figure 3d, left histograms) . Statistical analysis of results from three Pts with melanoma showed that the percent inhibition of CD56+ Vγ9γT cells in the presence of anti-CD56 mAb was significantly higher than that in the presence of control IgG1 [51.3 ± 10.6% inhibition with anti-CD56 mAb and 3.6 ± 4.1% inhibition with mouse IgG1, p<0.001 (Figure 3d, right columns) ].
Results
Phenotypical
Then, we assessed productions of IFNγ and TNFα by CD56+ Vγ9γδT cells in comparison with those by CD56-Vγ9γδT cells. As representative results from Pt. 2 with NSCLC shown in Figure 4a , productions of IFNγ and TNFα by V9γδT cells expressing high levels of CD56 (fraction A; the percentage of CD56+ cells among Vγ9γδT cells was 98.6%) were higher than those by Vγ9γδT cells expressing low levels of CD56 (fraction B; the percentage of CD56+ cells within Vγ9γδT cells was 10.7%). Statistical analysis from four cancer patients including two NSCLC patients and two metastatic melanoma patients showed that IFNγ and TNFα productions by Vγ9γδT cells expressing high levels of CD56 were significantly higher than those by Vγ9γδT 
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cells expressing low levels of CD56 [for IFNγ57.6 ± 5.5% vs 33.0 ± 2.5, p<0.03; for TNF-α, 52.9 ± 2.3 vs 31,4 ± 6.4%, p<0.05 (Figure 4b) ].
CD56 high+
IFN-DCs from Pts with NSCLC efficiently promote the expansion of CD56+Vγ9γδT cells expressing high levels of CD16 in the presence of IL-2 and zoledronate in vitro and in vivo
In the case of Pt1 with NSCLC, before culture, the percentage of V9γδT cells was 9.6%, among which the percentages of CD56, CD16, NKG2D, and CD69 were 59.5%, 31.2%, 94.9%, and 0.9%, respectively (Figure 5a ). After 14 day-culture of lymphocytes with CD56 high+ IFNDCs in the presence of IL-2 and zoledronate, the percentage of Vγ9γδT cells among lymphocytes was 90.2%, among which the percentages of CD56, CD16, NKG2D, and CD69 were 91.2%, 91.7%, 98.6%, and 60.1%, respectively (Figure 5a) . These results showed that in the case of Pt1, CD56 high+ IFN-DC-activated Vγ9γδT cells expressed high levels of CD56, CD16, NKG2D and CD69 in vitro. Note that in our own observations of forty cancer patients, including nine patients with NSCLC, following culture of PBMC in the presence of zoledronate and IL-2 for 14 days, the percentage of Vγ9γδT cells among lymphocytes was 81.8 ± 11.6%, among which the percentages of CD56+ cells and CD16+ cells were 30.1 ± 12.2% and 19.3 ± 12.2%, respectively. These results show that in comparison with using PBMC wherein monocytes play as APCs, the percentages of CD56+ cells and CD16+ cells among CD56 which were prepared from PBMCs in the presence of zoledronate and IL-2 described in the Materials and Methods, were cultured with 5.8 ± 3.5x10 6 (n=12) of autologous CD56 high+ IFN-DCs for 24 hours in the presence of zoledronate and IL-2, and then, the obtained CD56 high+ IFN-DC-activated Vγ9γδT cells were infused to Pt1 at approximately 2 or 3-week intervals. This vaccination is well tolerated by the patient without experiencing any adverse effects or clinical signs of autoimmune reactions. Tumor response was not a focus of this treatment, but it is of interest that following this vaccination sustained decreases in one of serum tumor marker, SLX, were observed. Each assessment was done using PBMCs which were collected just before each infusion. The percentage of V9γδT cells among PB lymphocytes was assessed firstly after two infusions. A total of eleven assessments of Vγ9γδT cells among PB lymphocytes were carried out (Figure 5b) . A total of 7 assessments of Vγ9γδT cells among PB lymphocytes, CD56+ Vγ9γδT cells among Vγ9γδT cells, and CD16+ V9γδT cells among Vγ9γδT cells following infusions were carried out (Figure 5c ). The percentage of Vγ9γδT cells among PB lymphocytes increased after two infusions from 9.6% (before infusion) to 19% after two infusions and this high percentage maintained following infusions [mean percentage of Vγ9γδT cells among lymphocytes ± SD with 7 infusions was 27.3 ± 4.9%) (Figure 5b Figure 6b and Figure 6c . Before infusion, the percentage of Vγ9γδT cells among PB lymphocytes was 9.3% which increased to 12.3% after 1 st infusion and 21.4% after 2 nd infusion and 20.7% after 4 th infusion (Figure 6b ). As shown in Figure 6c , before infusion, the percentages of CD56+, CD16+, and NKG2D+ cells among Vγ9γδT cells were 60.2%, 22.2%, and 99.1%, respectively (Figure 6c ). On 2 weeks later after 1 st infusion, the percentages of CD56+, CD16+, and NKG2D+ cells among Vγ9γδT cells were 78.9%, 86.7%, and 96.1% and these high percentages were kept following 2 nd infusion and 4 th infusion ( Figure  6c ). Note that even though there were no infusions for approximately 9 weeks (after 2 nd infusion and before 5 th infusion), the percentages of CD56+, CD16+, and NKG2D+ cells among Vγ9γδT cells were kept high (Figure 5b) . 
Discussion
In this study, we found that CD56 high+ IFN-DCs which may be a counterpart of circulating CD56+DC-like cells in human blood [21] , were differentiated from monocytes as adherent cells from Pts with various cancer in the presence of IFN-α and GM-CSF in vitro (Figure 1) . The CD56 high+ IFN-DCs derived from the Pts preferentially expanded CD56+ Vγ9γδT cells in the presence of zoledronate and IL-2 ( Figure 3c ). In particular, in the case of Pt1 and Pt2 with NSCLC, the CD56 high+ IFN-DCs preferentially expand Vγ9γδT cells which expressed high levels of CD56, CD16, NKG2D, and CD69 in vitro (Figure 5a and 6a) . Furthermore, the productions of IFNγ and TNFα by Vγ9γδT cells expressing high levels of CD56 were greater than those by Vγ9γδT cells expressing low levels of CD56 in vitro (Figure 4) . Taken together, these results with the previous study [19, 21] It is well known that, antigen receptors and adherent molecules are rearranged into a distinct concentration ring known as the immune synapse which is important for promoting activation signaling [22] . CD54 or ICAM-1 is a ligand for the leukocyte integrin complex CD11a/CD18 (LFA-1) and is expressed at different levels on a variety of cells, including APCs, T cells, and B cells [23] [24] [25] . The adhesive interaction between CD54 and LFA-1 facilitates cell-cell contact [25] and is thought to strengthen the immune synapse [26] . In the previous study [19] , we discussed that the expression levels of CD54 on CD56 It has been shown that like DCs, Vγ9γδT cells present antigens to αβ T cells and play APCs [27, 28] . In this study we confirmed that CD56 These in vivo observations for patients with NSCLC give us an important implication with immunotherapy for cancer Pts. Both Pts 1 and 2 had chemotherapy during immunotherapy with CD56 high+ IFN-DC-activated Vγ9γδT cells, however, high percentages of CD56+ Vγ9γδT cell and CD16+ Vγ9γδT cells among Vγ9γδT cell were maintained 4 to 8 weeks without the immunotherapy. In general, the percentage of Vγ9γδT cells among PB lymphocytes is lower in patients with cancer and varies between cancer Pts (2.2 ± 2.1%, n=45; in our unpublished observations). In contrast, the percentage of Vγ9γδT cells among PB lymphocytes from patients with NSCLC is similar to that from HDs (5 to 10%). Therefore, the expansion of Vγ9γδT cells from PBMCs of Pts with NSCLC is easier than that from PBMCs of other cancer patients and then, finally a large number of CD56 high+ IFN-DC-activated Vγ9γδT cells were obtained from Pts with NSCLC.
In this study we have conducted immunotherapy using CD56 
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